ClinicalTrials.gg
CompletedNCT05262855FAPI-46 PDACUpdated May 29, 2026Results posted

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

A Phase 2 interventional study of [68Ga]FAPI-46 in PDAC - Pancreatic Ductal Adenocarcinoma and FAP, sponsored by SOFIE. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by SOFIE · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

02

Conditions studied

  • PDAC - Pancreatic Ductal Adenocarcinoma
  • FAP

Keywords

  • Fibroblast Activation Protein Inhibitor (FAPI)
  • PDAC
03

In context

Lead sponsor

SOFIE is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed pancreatic ductal adenocarcinoma
  2. Treatment-naïve
  3. Staged as resectable or borderline-resectable
  4. Planned to undergo surgical resection or to receive therapy (i.e., chemotherapy, radiation therapy, or combination) and subsequent possible surgical resection
  5. Anatomic imaging (e.g., CT, MRI) obtained within ≤ 28 days of consent
  6. Age ≥ 18 years
  7. Completed as determined per the IRB of record

Exclusion criteria

Exclusion Criteria:

  1. Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of
  2. Declining to use effective methods during the study (for individuals of child-producing potential)
  3. Need for emergent surgery that would be delayed by participation
  4. Bacterial, viral, or fungal infections requiring systemic therapy
  5. Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or diseases or other conditions) that in the opinion of the investigator, physician of record and/or Sofie could compromise patient safety and/or protocol objectives.
  6. Known diagnosis of autoimmune disorders
  7. Patients receiving any other agent within the past 28 days
  8. Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the [68Ga]FAPI-46 injection.
  9. Known to any used in [68Ga]FAPI-46:

trace amounts of sodium acetate sodium ascorbate and/or hydrochloric acid

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    68Ga-FAPI-46 PET/CT

    Patients receive \[68Ga\]FAPI-46 intravenously followed by PET/CT 15-25 minutes later

    Drug: [68Ga]FAPI-46

Interventions

  • DrugFAPI-46Studies of FAPI-46FAPI-46 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    \[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).

06

What researchers measure

Primary outcomes

  1. Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard

    Sensitivity was defined as the proportion of participants with histopathology-confirmed PDAC who had a positive \[⁶⁸Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[⁶⁸Ga\]FAPI-46 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Higher sensitivity indicates a greater ability of \[⁶⁸Ga\]FAPI-46 PET to detect FAP-expressing disease and a lower likelihood of false-negative results, thereby reflecting the effectiveness of the imaging modality relative to the histopathological reference standard.

    Time frame: Day 1

Secondary outcomes

  1. Correlation Between [⁶⁸Ga]FAPI-46 PET Uptake (SUVmax) and IHC Staining Intensity (H-score) in FAP-positive Lesions

    The association between \[⁶⁸Ga\]FAPI-46 PET uptake, measured by maximum standardized uptake value (SUVmax), and FAP expression, assessed by H-score from histopathology, was evaluated. The relationship between SUVmax and H-score was assessed using the Spearman rank correlation coefficient, with corresponding 95% confidence intervals, in participants with evaluable PET imaging and histopathology results may not be linear owing in part to the H score ceiling of 300. All available paired PET and H-score measurements were included; when both pre- and post-neoadjuvant therapy data were available, each time point was analyzed separately. Spearman's rho was selected because it assesses monotonic relationships between ordinal or continuous variables and does not assume linearity, which may not be appropriate for the relationship between SUVmax and H-score.

    Time frame: Day 1

  2. Sensitivity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth

    Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[68Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[68Ga\]FAPI-46 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented considering IHC-positive results using 3 IHC cut-off values: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

    Time frame: Day 1

  3. Specificity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth

    Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[68Ga\]FAPI-46 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[68Ga\]FAPI-46 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated considering IHC-positive results using 3 IHC cut-off values \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

    Time frame: Day 1

  4. Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction.

    Time frame: Up to 2 years

07

Results

Posted May 29, 2026

Participant flow

This was a prospective, multicenter, single arm, open label, non-randomized study to evaluate the ability of \[68Ga\]FAPI-46 to detect fibroblast activation protein (FAP) expressing cells in participants with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Participant flow — Overall Study
Milestone[⁶⁸Ga]FAPI-46 PET/CT
Started63
Completed22
Not completed41
Withdrew: Death3
Withdrew: Physician decision5
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up1
Withdrew: Study drug not administered1
Withdrew: Other6
Withdrew: Progressive disease18

Outcome measures

PrimarySensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard

Sensitivity was defined as the proportion of participants with histopathology-confirmed PDAC who had a positive \[⁶⁸Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[⁶⁸Ga\]FAPI-46 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Higher sensitivity indicates a greater ability of \[⁶⁸Ga\]FAPI-46 PET to detect FAP-expressing disease and a lower likelihood of false-negative results, thereby reflecting the effectiveness of the imaging modality relative to the histopathological reference standard.

Time frame:
Day 1
Reported as:
Number · proportion of participants
Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard
proportion of participants68Ga-FAPI-46 PET/CT
Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard0.741 (0.647 to 0.836)
SecondaryCorrelation Between [⁶⁸Ga]FAPI-46 PET Uptake (SUVmax) and IHC Staining Intensity (H-score) in FAP-positive Lesions

The association between \[⁶⁸Ga\]FAPI-46 PET uptake, measured by maximum standardized uptake value (SUVmax), and FAP expression, assessed by H-score from histopathology, was evaluated. The relationship between SUVmax and H-score was assessed using the Spearman rank correlation coefficient, with corresponding 95% confidence intervals, in participants with evaluable PET imaging and histopathology results may not be linear owing in part to the H score ceiling of 300. All available paired PET and H-score measurements were included; when both pre- and post-neoadjuvant therapy data were available, each time point was analyzed separately. Spearman's rho was selected because it assesses monotonic relationships between ordinal or continuous variables and does not assume linearity, which may not be appropriate for the relationship between SUVmax and H-score.

Time frame:
Day 1
Reported as:
Number · Correlation coefficient
Correlation Between [⁶⁸Ga]FAPI-46 PET Uptake (SUVmax) and IHC Staining Intensity (H-score) in FAP-positive Lesions
Correlation coefficient68Ga-FAPI-46 PET/CT
Correlation Between [⁶⁸Ga]FAPI-46 PET Uptake (SUVmax) and IHC Staining Intensity (H-score) in FAP-positive Lesions0.137 (-0.257 to 0.491)
SecondarySensitivity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth

Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[68Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[68Ga\]FAPI-46 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented considering IHC-positive results using 3 IHC cut-off values: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Sensitivity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth
Proportion of participants68Ga-FAPI-46 PET/CT
IHC Cutoff: >500.697 (0.540 to 0.854)
IHC Cutoff: >1000.700 (0.536 to 0.864)
IHC Cutoff: >2000.636 (0.352 to 0.921)
SecondarySpecificity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth

Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[68Ga\]FAPI-46 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[68Ga\]FAPI-46 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated considering IHC-positive results using 3 IHC cut-off values \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Specificity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth
Proportion of participants68Ga-FAPI-46 PET/CT
IHC Cutoff: >501.000 (1.000 to 1.000)
IHC Cutoff: >1000.500 (0.010 to 0.990)
IHC Cutoff: >2000.304 (0.116 to 0.492)
SecondaryNumber of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Participants[⁶⁸Ga]FAPI-46 PET/CT
Any TEAE3
Any Serious TEAE1

Adverse events

Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[⁶⁸Ga]FAPI-46 PET/CT3/63 (4.8%)1/58 (1.7%)3/58 (5.2%)
Most frequent serious events
Most frequent serious events
Event[⁶⁸Ga]FAPI-46 PET/CT
Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/58
Most frequent other events
Most frequent other events
Event[⁶⁸Ga]FAPI-46 PET/CT
AnaemiaBlood and lymphatic system disorders1/58
Lymphocyte count decreasedInvestigations1/58
Dermatitis contactSkin and subcutaneous tissue disorders1/58

Baseline characteristics

Safety Analysis Set which comprises of all participants who received any amount of \[68Ga\]FAPI-46.

Age, Continuous
Age, Continuous(Years)[⁶⁸Ga]FAPI-46 PET/CT
Mean69.0 ± 8.96
Sex: Female, Male
Sex: Female, Male(Participants)[⁶⁸Ga]FAPI-46 PET/CT
Female25
Male33
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)[⁶⁸Ga]FAPI-46 PET/CT
Hispanic or Latino5
Not Hispanic or Latino48
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)[⁶⁸Ga]FAPI-46 PET/CT
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White40
More than one race0
Unknown or Not Reported15
08

Study locations

4 sites
  • University of California Los Angeles (UCLA) Health
    Los Angeles, California 90095, United States
  • BAMF Health
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • NYU Langone Health
    New York, New York 10016, United States
09

References and documents

Publications

  • Karbhari A, Mosessian S, Trivedi KH, Valla F Jr, Jacobson M, Truty MJ, Patnam NG, Simeone DM, Zan E, Brennan T, Chen H, Kuo PH, Herrmann K, Goenka AH. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol. PLoS One. 2023 Nov 27;18(11):e0294564. doi: 10.1371/journal.pone.0294564. eCollection 2023. PubMed 38011131 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Mar 2025, 34 months.

Results were first posted in May 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Mar 2, 2022
StartActual
May 2, 2022
Primary completionActual
Mar 7, 2025
CompletionActual
Nov 4, 2025
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05262855
Lead sponsor
SOFIE
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
May 2, 2022
Primary completion
Mar 7, 2025
Completion
Nov 4, 2025
Results posted
May 29, 2026
Last update
May 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FAPI-46

Start the discussion